Psychiatry Research: Neuroimaging, 45:245-246
Elsevier

Reviewers for 1992

We wish to acknowledge the important assistance we have received from many scientists, who, along with the Editorial Board, have evaluated manuscripts submitted for publication during 1992. All outside reviewers are listed in the December issue of *Psychiatry Research* (Volume 44, Number 3, 1992).

Author Index for 1992

Abbruzzese, M. 45:115
Adams, R.N. 45:203
Agartz, I. 45:139
Aigner, T.G. 45:153
Alliger, R. 45:33
Amass, L. 45:15
Anderer, P. 45:79
Andreasen, N.C. 45:33
Arndt, S. 45:33
Ashtari, M. 45:1
Baldwin, R.M. 45:67
Barbanoj, M.J. 45:79
Berman, K.F. 45:187
Bird, E.D. 45:203
Bjurling, P. 45:215
Bogerts, B. 45:1
Bossuyt, A. 45:227
Bossuyt-Piron, C. 45:227
Charney, D.S. 45:67
Cohen, G. 45:33
Cohen, R.M. 45:153
Colombo, C. 45:115
Cooper, J.E. 45:123
Coppola, R. 45:105
Coppola, R. 45:187
Costa, D.C. 45:143
D'haenen, H. 45:215
Degreef, G. 45:1
Dey, H.M. 45:67
Doudet, D.J. 45:153
Ebert, D. 45:239
Ehrhardt, J. 45:33
Ell, P.G. 45:143
Fairbanks, L.A. 45:177
Falkai, P. 45:1
Feistel, H. 45:239
Ford, R.A. 45:209
George, M.S. 45:143
Germine, M. 45:67
Gijsemans, M. 45:227
Gleason, R.P. 45:25
Goddard, A.W. 45:67
Greve, B. 45:1
Guze, B.H. 45:169
Guze, B.H. 45:177
Harrison, G. 45:123
Hartvig, P. 45:215
Heninger, G.R. 45:67
Hoffer, P.B. 45:67
Innis, R.B. 45:67
Inubushi, T. 45:53
Jones, D.W. 45:187
Karson, C.N. 45:95
Kaschka, W. 45:239
Kato, T. 45:53
Kaufman, L. 45:227
Kihlberg, T. 45:215
Komoroski, R.A. 45:95
Kuan, J. 45:33
Långström, B. 45:215
Lantos, G. 45:1
Lencz, T. 45:123
Lewis, S.W. 45:209
Lieberman, J. 45:1
Livian, S. 45:115
Locatelli, M. 45:115
Lundqvist, H. 45:215
Mandelkern, M.A. 45:177
Marenco, S. 45:187
Marions, O. 45:139
McLellan, C.A. 45:153
Medley, I. 45:123
Mendelson, J.H. 45:15
Mertens, J. 45:227
Min, C.A. 45:177
Mohanakrishnan, P. 45:95
Nardin, R. 45:15
Newman, F. 45:105
Newton, J.E.O. 45:95
Oke, A.F. 45:203
Pawluczyk, S. 45:25
Pollock, V.E. 45:25
Putz, C. 45:203
Raine, A. 45:123
Reibring, L. 45:215
Reveley, A. 45:209
Reynolds, G.P. 45:123
Reynolds, L.M. 45:123

Ring, H.A. 45:143
Robertson, M.M. 45:143
Ronchi, P. 45:115
Sääf, J. 45:139
Saletu, B. 45:79
Scarone, S. 45:115
Schneider, L.S. 45:25
Scotti, G. 45:115
Seibyl, J.P. 45:67
Semlitsch, H.V. 45:79
Sheard, C. 45:123
Small, G.W. 45:177
Smeraldi, E. 45:115
Smith, E.O. 45:67
Sprigg, J. 45:95
Stein, M.B. 45:105
Stern, C.E. 45:177
Syed, G.M.S. 45:209
Szuba, M.P. 45:169
Takahashi, S. 45:53
Tedroff, J. 45:215
Teoh, S.K. 45:15
Toone, B.K. 45:209
Trettau, J.R. 45:105
Trimble, M.R. 45:143
Uhde, T.W. 45:105
Wahlund, L.-O. 45:139
Weinberger, D.R. 45:187
Wetterberg, L. 45:139
Woods, B.T. 45:15
Woods, S.W. 45:67
Yuh, W.T.C. 45:33
Zemansky, M.F. 45:25
Zoghbi, S.S. 45:67

Psychiatry Research: Neuroimaging, 45:247-253
Elsevier

Subject Index for 1992

Affective disorder
age, leukoencephalopathy, 45:159
age, MRI, 45:159
bipolar subtype, lithium-7 brain concentration, 45:53
bipolar subtype, MRI spectroscopy, 45:53
ketanserin, serotonin$_2$ receptor, 45:227
ketanserin, SPECT, 45:227
leukoencephalopathy, age, 45:159
leukoencephalopathy, MRI, 45:159
lithium-7 brain concentration, bipolar subtype, 45:53
lithium-7 brain concentration, MRI spectroscopy, 45:53
MRI, age, 45:159
MRI, leukoencephalopathy, 45:159
MRIspectroscopy, bipolar subtype, 45:53
MRIspectroscopy, lithium-7 brain concentration, 45:53
serotonin$_2$ receptor, ketanserin, 45:227
serotonin$_2$ receptor, SPECT, 45:227
SPECT, ketanserin, 45:227
SPECT, serotonin$_2$ receptor, 45:227
Age
affective disorder, leukoencephalopathy, 45:159
affective disorder, MRI, 45:159
leukoencephalopathy, affective disorder, 45:159
leukoencephalopathy, MRI, 45:159
MRI, affective disorder, 45:159
MRI, leukoencephalopathy, 45:159
Alcoholism
electroencephalography, topographic mapping, 45:25
topographic mapping, electroencephalography, 45:25
Benzodiazepines
iomazenil, normal controls, 45:67
iomazenil, occipital lobes, 45:67
iomazenil, SPECT, 45:67
normal controls, iomazenil, 45:67
normal controls, occipital lobes, 45:67
normal controls, SPECT, 45:67
occipital lobes, iomazenil, 45:67
occipital lobes, normal controls, 45:67
occipital lobes, SPECT, 45:67
SPECT, iomazenil, 45:67
SPECT, normal controls, 45:67
SPECT, occipital lobes, 45:67
Blood flow
catatonic syndrome, temporal lobe, 45:239
schizophrenia, catatonic syndrome, 45:239
Blood flow continued
schizophrenia, SPECT, 45:239
schizophrenia, temporal lobe, 45:239
SPECT, catatonic syndrome, 45:239
SPECT, schizophrenia, 45:239
SPECT, temporal lobe, 45:239
temporal lobe, catatonic syndrome, 45:239
temporal lobe, schizophrenia, 45:239
temporal lobe, SPECT, 45:239
Caffeine
electroencephalography, panic disorder, 45:105
panic disorder, electroencephalography, 45:105
panic disorder, topographic mapping, 45:105
topographic mapping, panic disorder, 45:105
Caudate nucleus
MRI, obsessive-compulsive disorder, 45:115
obsessive-compulsive disorder, MRI, 45:115
Cavum septum pellucidum
MRI, schizophrenia, 45:1
post-mortem studies, schizophrenia, 45:1
schizophrenia, MRI, 45:1
schizophrenia, post-mortem studies, 45:1
Cerebrospinal fluid
image processing, MRI, 45:33
image processing, segmentation methodology, 45:33
MRI, image processing, 45:33
MRI, segmentation methodology, 45:33
segmentation methodology, image processing, 45:33
segmentation methodology, MRI, 45:33
Cocaine
heroin, MRI, 45:15
MRI, heroin, 45:15
MRI, substance abuse, 45:15
substance abuse, MRI, 45:15
Computed tomography
frontal lobe, schizophrenia, 45:209
frontal lobe, SPECT, 45:209
frontal lobe, ventricular size, 45:209
schizophrenia, frontal lobe, 45:209
schizophrenia, SPECT, 45:209
schizophrenia, ventricular size, 45:209
SPECT, frontal lobe, 45:209
SPECT, schizophrenia, 45:209
SPECT, ventricular size, 45:209
ventricular size, frontal lobe, 45:209
ventricular size, schizophrenia, 45:209
ventricular size, SPECT, 45:209
DOPA-F^{18}
MPTP, PET, 45:153
MPTP, primates, 45:153

DOPA-F^{18} continued
PET, MPTP, 45:153
PET, primates, 45:153
primates, MPTP, 45:153
primates, PET, 45:153
Dopamine
Huntington's disease, neuroleptics, 45:203
Huntington's disease, post-mortem study, 45:203
Huntington's disease, schizophrenia, 45:203
Huntington's disease, thalamus, 45:203
neuroleptics, Huntington's disease, 45:203
neuroleptics, post-mortem study, 45:203
neuroleptics, schizophrenia, 45:203
neuroleptics, thalamus, 45:203
post-mortem study, Huntington's disease, 45:203
post-mortem study, neuroleptics, 45:203
post-mortem study, schizophrenia, 45:203
post-mortem study, thalamus, 45:203
schizophrenia, Huntington's disease, 45:203
schizophrenia, neuroleptics, 45:203
schizophrenia, post-mortem study, 45:203
schizophrenia, thalamus, 45:203
thalamus, Huntington's disease, 45:203
thalamus, neuroleptics, 45:203
thalamus, post-mortem study, 45:203
thalamus, schizophrenia, 45:203
Electroencephalography
alcoholism, topographic mapping, 45:25
artifact elimination, topographic mapping, 45:79
caffeine, panic disorder, 45:105
caffeine, topographic mapping, 45:105
panicdisorder, caffeine, 45:105
panicdisorder, topographic mapping, 45:105
topographic mapping, alcoholism, 45:25
topographic mapping, artifact elimination, 45:79
topographic mapping, caffeine, 45:105
topographic mapping, panic disorder, 45:105
Fluoxetine
MR spectroscopy, neuroleptics, 45:95
MR spectroscopy, schizophrenia, 45:95
MR spectroscopy, trifluoperazine, 45:95
neuroleptics, MR spectroscopy, 45:95
neuroleptics, schizophrenia, 45:95
schizophrenia, MR spectroscopy, 45:95
schizophrenia, neuroleptics, 45:95
schizophrenia, trifluoperazine, 45:95
trifluoperazine, MR spectroscopy, 45:95
trifluoperazine, schizophrenia, 45:95
Frontal lobes
computed tomography, schizophrenia, 45:209
Frontal lobes continued
computed tomography, SPECT, 45:209
computed tomography, ventricular size, 45:209
hydroxytryptophan-C^{11}, PCPA, 45:215
hydroxytryptophan-C^{11}, PET, 45:215
MRI, neuropsychological tests, 45:123
MRI, schizophrenia, 45:123
MRI, Wisconsin Card Sort Test, 45:123
neuropsychological tests, MRI, 45:123
neuropsychological tests, schizophrenia, 45:123
obsessive-compulsive disorder, SPECT, 45:143
obsessive-compulsive disorder, Tourette's syndrome, 45:143
PCPA, hydroxytryptophan-C^{11}, 45:215
PCPA, PET, 45:215
PET, hydroxytryptophan-C^{11}, 45:215
PET, PCPA, 45:215
schizophrenia, computed tomography, 45:209
schizophrenia, MRI, 45:123
schizophrenia, neuropsychological tests, 45:123
schizophrenia, SPECT, 45:209
schizophrenia, ventricular size, 45:209
schizophrenia, Wisconsin Card Sort Test, 45:123
SPECT, computed tomography, 45:209
SPECT, obsessive-compulsive disorder, 45:143
SPECT, schizophrenia, 45:209
SPECT, Tourette's syndrome, 45:143
SPECT, ventricular size, 45:209
Tourette's syndrome, obsessive-compulsive disorder, 45:143
Tourette's syndrome, SPECT, 45:143
ventricular size, computed tomography, 45:209
ventricular size, schizophrenia, 45:209
ventricular size, SPECT, 45:209
Wisconsin Card Sort Test, MRI, 45:123
Wisconsin Card Sort Test, schizophrenia, 45:123
Heroin
cocaine, MRI, 45:15
MRI, cocaine, 45:15
MRI, substance abuse, 45:15
substance abuse, MRI, 45:15
Huntington's disease
dopamine, neuroleptics, 45:203
dopamine, post-mortem study, 45:203
dopamine, schizophrenia, 45:203
dopamine, thalamus, 45:203
neuroleptics, dopamine, 45:203
neuroleptics, post-mortem study, 45:203
neuroleptics, schizophrenia, 45:203
neuroleptics, thalamus, 45:203

Huntington's disease continued
post-mortem study, dopamine, 45:203
post-mortem study, neuroleptics, 45:203
post-mortem study, schizophrenia, 45:203
post-mortem study, thalamus, 45:203
schizophrenia, dopamine, 45:203
schizophrenia, neuroleptics, 45:203
schizophrenia, post-mortem study, 45:203
schizophrenia, thalamus, 45:203
thalamus, dopamine, 45:203
thalamus, neuroleptics, 45:203
thalamus, post-mortem study, 45:203
thalamus, schizophrenia, 45:203
5-Hydroxytryptophan
frontal lobe, PCPA, 45:215
frontal lobe, PET, 45:215
PCPA, frontal lobe, 45:215
PCPA, PET, 45:215
PET, frontal lobe, 45:215
PET, PCPA, 45:215
Image processing
cerebrospinal fluid, MRI, 45:33
cerebrospinal fluid, segmentation methodology, 45:33
MRI, cerebrospinal fluid, 45:33
MRI, segmentation methodology, 45:33
segmentation methodology, cerebrospinal fluid, 45:33
segmentation methodology, MRI, 45:33
Iomazenil
benzodiazepine receptor ligand, normal controls, 45:67
benzodiazepine receptor ligand, occipital lobes, 45:67
benzodiazepine receptor ligand, SPECT, 45:67
normal controls, benzodiazepine receptor ligand, 45:67
normal controls, occipital lobes, 45:67
normal controls, SPECT, 45:67
occipital lobes, benzodiazepine receptor ligand, 45:67
occipital lobes, normal controls, 45:67
occipital lobes, SPECT, 45:67
SPECT, benzodiazepine receptor ligand, 45:67
SPECT, normal controls, 45:67
SPECT, occipital lobes, 45:67
Ketanserin
affective disorder, serotonin$_2$ receptor, 45:227
affective disorder, SPECT, 45:227
serotonin$_2$ receptor, affective disorder, 45:227
serotonin$_2$ receptor, SPECT, 45:227
SPECT, affective disorder, 45:227
SPECT, serotonin$_2$ receptor, 45:227
Leukoencephalopathy
affective disorder, age, 45:159
affective disorder, MRI, 45:159
age, affective disorder, 45:159
age, MRI, 45:159
MRI, affective disorder, 45:159
MRI, age, 45:159
Lithium
affective disorder, MRI spectroscopy, 45:53
bipolar subtype, MRI spectroscopy, 45:53
MRI spectroscopy, affective disorder, 45:53
MRI spectroscopy, bipolar subtype, 45:53
MPTP (1-methyl-4-phenyl-1,2,3,6-tetra hydropyridine)
DOPA-F^{18}, PET, 45:153
DOPA-F^{18}, primates, 45:153
PET, DOPA-F^{18}, 45:153
PET, primates, 45:153
primates, DOPA-F-18, 45:153
primates, PET, 45:153
MRI (magnetic resonance imaging)
affective disorder, age, 45:159
affective disorder, leukoencephalopathy, 45:159
age, affective disorder, 45:159
age, leukoencephalopathy, 45:159
caudate nucleus, obsessive-compulsive disorder, 45:115
cavum septum pellucidum, post-mortem studies, 45:1
cavum septum pellucidum, schizophrenia, 45:1
cerebrospinal fluid, imageprocessing, 45:33
cerebrospinal fluid, segmentation methodology, 45:33
cocaine, heroin, 45:15
frequency of brain pathology, psychiatric patients, 45:139
frontal lobe, neuropsychological tests, 45:123
frontal lobe, schizophrenia, 45:123
frontal lobe, Wisconsin Card Sort Test, 45:123
heroin, cocaine, 45:15
image processing, cerebrospinal fluid, 45:33
image processing, segmentation methodology, 45:33
leukoencephalopathy, affective disorder, 45:159
leukoencephalopathy, age, 45:159
neuropsychological tests, frontal lobe, 45:123
neuropsychological tests, schizophrenia, 45:123
obsessive-compulsive disorder, caudate nucleus, 45:115
post-mortem studies, cavum septum

MRI continued
pellucidum, 45:1
post-mortem studies, schizophrenia, 45:1
psychiatric patients, frequency of brain pathology, 45:139
schizophrenia, cavum septum pellucidum, 45:1
schizophrenia, frontal lobe, 45:123
schizophrenia, neuropsychological tests, 45:123
schizophrenia, post-mortem studies, 45:1
schizophrenia, Wisconsin Card Sort Test, 45:123
segmentation methodology, cerebrospinal fluid, 45:33
segmentation methodology, image processing, 45:33
substance abuse, 45:15
Wisconsin Card Sort Test, frontal lobe, 45:123
Wisconsin Card Sort Test, schizophrenia, 45:123
MR (magnetic resonance) spectroscopy
affective disorder, lithium-7 brain concentration, 45:53
bipolar subtype, lithium-7 brain concentration, 45:53
fluoxetine, neuroleptics, 45:95
fluoxetine, schizophrenia, 45:95
fluoxetine, trifluoperazine, 45:95
lithium-7 brain concentration, affective disorder, 45:53
lithium-7 brain concentraiton, bipolar subtype, 45:53
neuroleptics, fluoxetine, 45:95
neuroleptics, schizophrenia, 45:95
schizophrenia, fluoxetine, 45:95
schizophrenia, neuroleptics, 45:95
schizophrenia, trifluoperazine, 45:95
trifluoperazine, fluoxetine, 45:95
trifluoperazine, schizophrenia, 45:95
Neuroleptics
dopamine, Huntington's disease, 45:203
dopamine, post-mortem study, 45:203
dopamine, schizophrenia, 45:203
dopamine, thalamus, 45:203
fluoxetine, trifluoperazine, 45:95
Huntington's disease, dopamine, 45:203
Huntington's disease, post-mortem study, 45:203
Huntington's disease, schizophrenia, 45:203
Huntington's disease, thalamus, 45:203
MR spectroscopy, schizophrenia, 45:95
MR spectroscopy, trifluoperazine, 45:95
post-mortem study, dopamine, 45:203
post-mortem study, Huntington's disease, 45:203
Neuroleptics continued
post-mortem study, schizophrenia, 45:203
post-mortem study, thalamus, 45:203
schizophrenia, dopamine, 45:203
schizophrenia, Huntington's disease, 45:203
schizophrenia, MR spectroscopy, 45:95
schizophrenia, post-mortem study, 45:203
schizophrenia, thalamus, 45:203
schizophrenia, trifluoperazine, 45:95
thalamus, dopamine, 45:203
thalamus, Huntington's disease, 45:203
thalamus, post-mortem study, 45:203
thalamus, schizophrenia, 45:203
trifluoperazine, fluoxetine, 45:95
trifluoperazine, MR spectroscopy, 45:95
trifluoperazine, schizophrenia, 45:95
Neuropsychological tests
frontal lobe, MRI, 45:123
frontal lobe, schizophrenia, 45:123
frontal lobe, Wisconsin Card Sort Test, 45:123
MRI, frontal lobe, 45:123
MRI, schizophrenia, 45:123
MRI, Wisconsin Card Sort Test, 45:123
schizophrenia, frontal lobe, 45:123
schizophrenia, MRI, 45:123
schizophrenia, Wisconsin Card Sort Test, 45:123
Wisconsin Card Sort Test, frontal lobe, 45:123
Wisconsin Card Sort Test, MRI, 45:123
Wisconsin Card Sort Test, schizophrenia, 45:123
Obsessive-compulsive disorder
caudate nucleus, MRI, 45:115
frontal lobe, SPECT, 45:143
frontal lobe, Tourette's syndrome, 45:143
MRI, caudate nucleus, 45:115
SPECT, frontal lobe, 45:143
SPECT, Tourette's syndrome, 45:143
Tourette's syndrome, frontal lobe, 45:143
Tourette's syndrome, SPECT, 45:143
Occipital lobe
benzodiazepine receptor ligand, iomazenil, 45:67
benzodiazepine receptor ligand, normal controls, 45:67
benzodiazepine receptor ligand, SPECT, 45:67
iomazenil, normal controls, 45:67
iomazenil, SPECT, 45:67
normal controls, benzodiazepine receptor ligand, 45:67
normal controls, iomazenil, 45:67
normal controls, SPECT, 45:67

Occipital lobe continued
SPECT, benzodiazepine receptor ligand, 45:67
SPECT, iomazenil, 45:67
SPECT, normal controls, 45:67
Panic disorder
caffeine, electroencephalography, 45:105
caffeine, topographic mapping, 45:105
electroencephalography, caffeine, 45:105
topographic mapping, caffeine, 45:105
PCPA (para-chlorophenylalanine)
frontal lobe, hydroxytryptophan-C^{11}, 45:215
frontal lobe, PET, 45:215
hydroxytryptophan-C^{11}, frontal lobe, 45:215
hydroxytryptophan-C^{11}, PET, 45:215
PET, frontallobe, 45:215
PET, hydroxytryptophan-C^{11}, 45:215
PET (positron emission tomography)
DOPA-F^{18}, MPTP, 45:153
DOPA-F^{18}, primates, 45:153
frontal lobe, hydroxytryptophan-C^{11}, 45:215
frontal lobe, PCPA, 45:215
hydroxytryptophan-C^{11}, frontal lobe, 45:215
hydroxytryptophan-C11, PCPA, 45:215
MPTP, DOPA-F18, 45:153
MPTP, primates, 45:153
PCPA, frontallobe, 45:215
PCPA, hydroxytryptophan-C^{11}, 45:215
primates, DOPA-F^{18}, 45:153
primates, MPTP, 45:153
region of interest methodology, reliability, 45:177
Primates
DOPA-F^{18}, MPTP, 45:153
DOPA-F^{18}, PET, 45:153
MPTP, DOPA-F^{18}, 45:153
MPTP, PET, 45:153
PET, DOPA-F^{18}, 45:153
PET, MPTP, 45:153
Schizophrenia
blood flow, catatonic syndrome, 45:239
blood flow, SPECT, 45:239
blood flow, temporal lobe, 45:239
catatonic syndrome, blood flow, 45:239
catatonic syndrome, SPECT, 45:239
catatonic syndrome, temporal lobe, 45:239
cavum septum pellucidum, MRI, 45:1
cavum septum pellucidum, post-mortem studies, 45:1
computed tomography, frontal lobe, 45:209
computed tomography, SPECT, 45:209
computed tomography, ventricular size, 45:209
dopamine, Huntington's disease, 45:203
dopamine, neuroleptics, 45:203
Schizophrenia continued
dopamine, post-mortem study, 45:203
dopamine, thalamus, 45:203
fluoxetine, MR spectroscopy, 45:95
fluoxetine, neuroleptics, 45:95
fluoxetine, trifluoperazine, 45:95
frontal lobe, computed tomography, 45:209
frontal lobe, MRI, 45:123
frontal lobe, neuropsychological tests, 45:123
frontal lobe, SPECT, 45:209
frontal lobe, ventricular size, 45:209
frontal lobe, Wisconsin Card Sort Test, 45:123
Huntington's disease, dopamine, 45:203
Huntington's disease, neuroleptics, 45:203
Huntington's disease, post-mortem study, 45:203
Huntington's disease, thalamus, 45:203
MR spectroscopy, fluoxetine, 45:95
MR spectroscopy, neuroleptics, 45:95
MR spectroscopy, trifluoperazine, 45:95
MRI, cavum septum pellucidum, 45:1
MRI, frontal lobe, 45:123
MRI, neuropsychological tests, 45:123
MRI, post-mortem studies, 45:1
MRI, Wisconsin Card Sort Test, 45:123
neuroleptics, dopamine, 45:203
neuroleptics, fluoxetine, 45:95
neuroleptics, Huntington's disease, 45:203
neuroleptics, MR spectroscopy, 45:95
neuroleptics, post-mortem study, 45:203
neuroleptics, thalamus, 45:203
neuropsychological tests, frontal lobe, 45:123
neuropsychological tests, MRI, 45:123
post-mortem studies, cavum septum pellucidum, 45:1
post-mortem studies, MRI, 45:1
post-mortem study, dopamine, 45:203
post-mortem study, Huntington's disease, 45:203
post-mortem study, neuroleptics, 45:203
post-mortem study, thalamus, 45:203
SPECT, blood flow, 45:239
SPECT, catatonic syndrome, 45:239
SPECT, computed tomography, 45:209
SPECT, frontal lobe, 45:209
SPECT, temporal lobe, 45:239
SPECT, ventricular size, 45:239
temporal lobe, blood flow, 45:239
temporal lobe, catatonic syndrome, 45:239
temporal lobe, SPECT, 45:239
thalamus, dopamine, 45:203
thalamus, Huntington's disease, 45:203
thalamus, neuroleptics, 45:203
thalamus, post-mortem study, 45:203

Schizophrenia continued
trifluoperazine, fluoxetine, 45:95
trifluoperazine, MR spectroscopy, 45:95
ventricular size, computed tomography, 45:209
ventricular size, frontal lobe, 45:209
ventricular size, SPECT, 45:209
Wisconsin Card Sort Test, frontal lobe, 45:123
Wisconsin Card Sort Test, MRI, 45:123
Segmentation techniques
cerebrospinal fluid, image processing, 45:33
cerebrospinal fluid, MRI, 45:33
image processing, cerebrospinal fluid, 45:33
image processing, MRI, 45:33
MRI, cerebrospinal fluid, 45:33
MRI, image processing, 45:33
Serotonin
affective disorder, ketanserin, 45:227
affective disorder, SPECT, 45:227
ketanserin, affective disorder, 45:227
ketanserin, SPECT, 45:227
SPECT, affective disorder, 45:227
SPECT, ketanserin, 45:227
SPECT (single photon emission computed tomography)
affective disorder, ketanserin, 45:227
affective disorder, serotonin$_2$ receptor, 45:227
benzodiazepine receptor ligand, iomazenil, 45:67
benzodiazepine receptor ligand, normal controls, 45:67
benzodiazepine receptor ligand, occipital lobes, 45:67
blood flow, xenon-133 vs. xenon-127, 45:187
bloodflow, catatonic syndrome, 45:239
bloodflow, schizophrenia, 45:239
bloodflow, temporal lobe, 45:239
catatonic syndrome, blood flow, 45:239
catatonic syndrome, schizophrenia, 45:239
catatonic syndrome, temporal lobe, 45:239
computed tomography, frontal lobe, 45:239
computed tomography, schizophrenia, 45:209
computed tomography, ventricular size, 45:209
frontal lobe, computed tomography, 45:209
frontal lobe, obsessive-compulsive disorder, 45:143
frontal lobe, schizophrenia, 45:209
frontal lobe, Tourette's syndrome, 45:143
frontal lobe, ventricular size, 45:209
iomazenil, benzodiazepine receptor ligand, 45:67
iomazenil, normal controls, 45:67
iomazenil, occipital lobes, 45:67
SPECT continued
ketanserin, affective disorder, 45:227
ketanserin, serotonin$_2$ receptor, 45:227
normal controls, benzodiazepine receptor ligand, 45:67
normal controls, iomazenil, 45:67
normal controls, occipital lobes, 45:67
obsessive-compulsive disorder, frontal lobe, 45:143
obsessive-compulsive disorder, Tourette's syndrome, 45:143
occipital lobes, benzodiazepine receptor ligand, 45:67
occipital lobes, iomazenil, 45:67
occipital lobes, normal controls, 45:67
schizophrenia, bloodflow, 45:239
schizophrenia, catatonic syndrome, 45:239
schizophrenia, computed tomography, 45:209
schizophrenia, frontal lobe, 45:209
schizophrenia, temporal lobe, 45:239
schizophrenia, ventricular size, 45:209
serotonin$_2$ receptor, affective disorder, 45:227
serotonin$_2$ receptor, ketanserin, 45:227
temporal lobe, bloodflow, 45:239
temporal lobe, catatonic syndrome, 45:239
temporal lobe, schizophrenia, 45:239
Tourette's syndrome, frontal lobe, 45:143
Tourette's syndrome, obsessive-compulsive disorder, 45:143
ventricular size, computed tomography, 45:209
ventricular size, frontallobe, 45:209
ventricular size, schizophrenia, 45:209
xenon-133 vs. xenon-127, blood flow, 45:187
Substance abuse (see also **Alcoholism**)
cocaine, MRI, 45:15
heroin, MRI, 45:15
MRI, cocaine, 45:15
MRI, heroin, 45:15
Temporal lobe
blood flow, catatonic syndrome, 45:239
blood flow, schizophrenia, 45:239
blood flow, SPECT, 45:239
catatonic syndrome, blood flow, 45:239
catatonic syndrome, schizophrenia, 45:239
catatonic syndrome, SPECT, 45:239
schizophrenia, blood flow, 45:239
schizophrenia, catatonic syndrome, 45:239
schizophrenia, SPECT, 45:239
SPECT, blood flow, 45:239
SPECT, catatonic syndrome, 45:239
SPECT, schizophrenia, 45:239
Thalamus
dopamine, Huntington's disease, 45:203
dopamine, neuroleptics, 45:203

Thalamus continued
dopamine, post-mortem study, 45:203
dopamine, schizophrenia, 45:203
Huntington's disease, dopamine, 45:203
Huntington's disease, neuroleptics, 45:203
Huntington's disease, post-mortem study, 45:203
Huntington's disease, schizophrenia, 45:203
neuroleptics, dopamine, 45:203
neuroleptics, Huntington's disease, 45:203
neuroleptics, post-mortem study, 45:203
neuroleptics, schizophrenia, 45:203
post-mortem study, dopamine, 45:203
post-mortem study, Huntington's disease, 45:203
post-mortem study, neuroleptics, 45:203
post-mortem study, schizophrenia, 45:203
schizophrenia, dopamine, 45:203
schizophrenia, Huntington's disease, 45:203
schizophrenia, neuroleptics, 45:203
schizophrenia, post-mortem study, 45:203
Topographic mapping
alcoholism, electroencephalography, 45:25
artifact elimination, electroencephalography, 45:79
caffeine, electroencephalography, 45:105
caffeine, panic disorder, 45:105
electroencephalography, alcoholism, 45:25
electroencephalography, artifact elimination, 45:79
electroencephalography, caffeine, 45:105
electroencephalography, panic disorder, 45:105
panic disorder, caffeine, 45:105
panic disorder, electroencephalography, 45:105
Tourette's syndrome
frontal lobe, obsessive-compulsive disorder, 45:143
frontal lobe, SPECT, 45:143
obsessive-compulsive disorder, frontal lobe, 45:143
obsessive-compulsive disorder, SPECT, 45:143
SPECT, frontal lobe, 45:143
SPECT, obsessive-compulsive disorder, 45:143
Trifluoperazine
fluoxetine, MR spectroscopy, 45:95
fluoxetine, schizophrenia, 45:95
MR spectroscopy, fluoxetine, 45:95
MRspectroscopy, schizophrenia, 45:95
schizophrenia, fluoxetine, 45:95
schizophrenia, MR spectroscopy, 45:95
Ventricular size
computed tomography, frontal lobe, 45:209
computed tomography, schizophrenia, 45:209
computed tomography, SPECT, 45:209
frontal lobe, computed tomography, 45:209
frontal lobe, schizophrenia, 45:209
frontal lobe, SPECT, 45:209
schizophrenia, computed tomography, 45:209
schizophrenia, frontal lobe, 45:209
schizophrenia, SPECT, 45:209
SPECT, computed tomography, 45:209
SPECT, frontallobe, 45:209
SPECT, schizophrenia, 45:209
Xenon-133 vs. xenon-127
blood flow, SPECT, 45:187
resolution, SPECT
SPECT, blood flow, 45:187